ArticleAnnals of surgical oncology2023

Enhanced Clinical Utility of Molecular Budding Signature as a Recurrence Risk Determinant in Stage II and III Colon Cancer Patients.

Eiji Shinto et al.PubMed ↗Publisher ↗

No numbers read from the abstract.